Therefore, CD44 may be a useful marker in T-ALL patients with NOTCH1 mutations that could help in the prognosis and evaluation of relapse risk and hence can be considered a potential target for future combined therapies (Figure 3). The gene discussed is CD44; the disease is acute lymphoblastic leukemia.